HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pemphigus — Clinical Guidelines

Overview

Pemphigus encompasses a group of life-threatening autoimmune blistering diseases characterized by autoantibodies against desmoglein proteins, leading to acantholysis and blister formation in the skin and mucous membranes 4 5.

Diagnosis

Clinical Presentation: Presence of flaccid blisters and erosions 4.

Tzanck Smear: Useful for initial cytodiagnosis, showing acantholytic cells 1.

Indirect Immunofluorescence (IIF): Essential for detecting anti-desmoglein antibodies; monkey esophagus and normal human skin are used as substrates 11.

Desmoglein ELISA: Provides accurate diagnosis and classification between pemphigus foliaceus and vulgaris 12.

Management

First-Line Treatment:

- Systemic Corticosteroids: High-dose prednisone (initial dose often 1-2 mg/kg/day) 4 7. - Immunosuppressants: - Azathioprine: Used to reduce steroid dependency 4. - Mycophenolate Mofetil: Alternative to azathioprine 4.

Adjunctive Therapies:

- Rituximab: Approved as first-line treatment for moderate to severe pemphigus vulgaris in Europe and the US; 4 weekly infusions of 375 mg/m2 5 8. - Antivirals/Antibiotics: Considered if secondary infections are present 4.

Special Populations

Pregnancy: Management requires careful balancing of maternal and fetal safety; often involves lower-dose corticosteroids and close monitoring 4.

Elderly: Increased risk of complications; treatment tailored to minimize side effects while controlling disease activity 4.

Comorbidities: Presence of other conditions may influence immunosuppressive regimen choices; close collaboration with specialists recommended 4.

Key Recommendations

Initiate high-dose corticosteroids as first-line therapy for pemphigus vulgaris and foliaceus (Evidence: Strong 4).

Consider rituximab as a first-line treatment for moderate to severe pemphigus vulgaris due to its efficacy and potential steroid-sparing effects (Evidence: Strong 5).

Use desmoglein ELISA for accurate diagnosis and differentiation between pemphigus subtypes (Evidence: Moderate 12).

Monitor and manage secondary infections rigorously due to the high risk in pemphigus patients (Evidence: Expert opinion 4).

Tailor immunosuppressive therapy in elderly patients to minimize adverse effects while maintaining disease control (Evidence: Moderate 4).

References

1 Chaudhari S, Meshram N, Bhatkule M, Srivastava A, Gadkari R. Tzanck Smear: Old Handy Tool in Modern Dermatology. Diagnostic cytopathology 2025. link 2 Niu Y, Lu H, He L, Wang Z, Duan X. Exploring drug-induced pemphigus findings from the FDA adverse event reporting system database. Medicine 2025. link 3 Baroukhian J, Seiffert-Sinha K, Sinha AA. A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic. Frontiers in immunology 2024. link 4 Chu CY, Lee CH, Lee HE, Cho YT, Hsu CK, Chan TC et al.. Taiwanese dermatological association (TDA) consensus for the management of pemphigus. Journal of the Formosan Medical Association = Taiwan yi zhi 2023. link 5 Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S et al.. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology : JEADV 2020. link 6 Murrell DF, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA et al.. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology 2020. link 7 Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. Anais brasileiros de dermatologia 2019. link 8 Gregoriou S, Giatrakou S, Theodoropoulos K, Katoulis A, Loumou P, Toumbis-Ioannou E et al.. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial. Dermatology (Basel, Switzerland) 2014. link 9 Grando SA, Holubar K, Schwartz RA. Jean-Claude Bystryn 1938-2010. An obituary. Experimental dermatology 2011. link 10 Hofmann SC, Kautz O, Hertl M, Sticherling M, Zillikens D, Bruckner-Tuderman L. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009. link 11 Ng PP, Thng ST, Mohamed K, Tan SH. Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus. The Australasian journal of dermatology 2005. link 12 Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Archives of dermatological research 2003. link 13 Nishikawa T, Hashimoto T, Shimizu H, Ebihara T, Amagai M. Pemphigus: from immunofluorescence to molecular biology. Journal of dermatological science 1996. link00459-9) 14 Amagai M. Adhesion molecules. I: Keratinocyte-keratinocyte interactions; cadherins and pemphigus. The Journal of investigative dermatology 1995. link 15 Shirahama S, Nham NX, Yagi H, Furukawa F, Takigawa M. Pemphigus associated with metastatic carcinoid. Dermatology (Basel, Switzerland) 1994. link 16 Lee CW, Ro YS. Pemphigus developed on preexisting dermatoses. The Journal of dermatology 1994. link 17 Iwata M, Watanabe S, Tamaki K. Pemphigus vegetans presenting as scrotal tongue. The Journal of dermatology 1989. link 18 Deschamps P, Pedailles S, Michel M, Leroy D. Photo-induction of lesions in a patient with pemphigus erythematosus. Photo-dermatology 1984. link

Pemphigus